Sökning: onr:"swepub:oai:DiVA.org:uu-524569" >
Treatment-free remi...
-
Flygt, HjalmarUppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden
(författare)
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
2024
-
Springer,2024
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-524569
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-524569URI
-
https://doi.org/10.1038/s41375-024-02145-6DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-111229URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:155228509URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-202359URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. Flygt, H., Söderlund, S., Richter, J. et al. Leukemia (2024). https://doi.org/10.1038/s41375-024-02184-z
-
Funding Agencies|Uppsala University
-
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for ≥ one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for ≥1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2nd stop. After a median follow-up of 27 months from 2nd stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR4 within a median of 3 months from TKI re-initiation. In summary, we show that a 2nd TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Söderlund, StinaUppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden
(författare)
-
Richter, JohanDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden
(författare)
-
Saussele, SusanneMedical Clinic, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany,Heidelberg Univ, Germany
(författare)
-
Koskenvesa, PerttuDepartment of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland,Hematol Res Unit Helsinki, Finland; Helsinki Univ Hosp, Finland
(författare)
-
Stenke, LeifKarolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden
(författare)
-
Mustjoki, SatuDepartment of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland; ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland,Hematol Res Unit Helsinki, Finland; Helsinki Univ Hosp, Finland; Univ Helsinki, Finland; Univ Helsinki, Finland; ICAN Digital Precis Canc Med Flagship, Finland
(författare)
-
Dimitrijevic, AndrejaDepartment of Hematology, Odense University Hospital, Odense, Denmark,Odense Univ Hosp, Denmark
(författare)
-
Stentoft, JesperDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark,Aarhus Univ Hosp, Denmark
(författare)
-
Majeed, WaleedDepartment of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway,Stavanger Univ Hosp, Norway
(författare)
-
Roy, LydiaFrench CML group Fi-LMC, Centre Léon Bérard, Lyon, Hôpital Universitaire Henri Mondor, AP-HP, Service d'hématologie Clinique & Faculté de Santé, Université Paris Est Créteil, Créteil, France,Univ Paris Est Creteil, France; Univ Paris Est Creteil, France
(författare)
-
Wolf, DominikDepartment of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Tyrolean Cancer Research Institute (TKFI), Medical University Innsbruck, Innsbruck, Austria; Medical Clinic 3, Universitätsklinikum, Bonn, Germany,Med Univ Innsbruck, Austria; Univ Klinikum Bonn, Germany
(författare)
-
Dreimane, ArtaDepartment of Hematology, Linköping University Hospital, Linköping, Sweden,Region Östergötland, Hematologiska kliniken US(Swepub:liu)artdr13
(författare)
-
Gjertsen, Bjørn ToreDepartment of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway,Haukeland Hosp, Norway
(författare)
-
Gedde-Dahl, TobiasDepartment of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway,Natl Hosp Norway, Norway
(författare)
-
Ahlstrand, Erik,1974-Region Örebro län,Örebro universitet, Institutionen för medicinska vetenskaper,Department of Medicine,Orebro Univ, Sweden(Swepub:oru)ead
(författare)
-
Markevärn, BeritDepartment of Hematology, Umeå University Hospital, Umeå, Sweden,Umea Univ Hosp, Sweden
(författare)
-
Hjorth-Hansen, HenrikDepartment of Hematology, St. Olavs Hospital, Trondheim, Norway,St Olavs Hosp, Norway
(författare)
-
Janssen, JeroenDepartment of Hematology, Radboud University medical center, Nijmegen, The Netherlands,Radboud Univ Nijmegen, Netherlands
(författare)
-
Olsson-Strömberg, UllaDepartment of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden
(författare)
-
Uppsala universitetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Leukemia: Springer0887-69241476-5551
Internetlänk
Hitta via bibliotek
-
Leukemia
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Flygt, Hjalmar
-
Söderlund, Stina
-
Richter, Johan
-
Saussele, Susann ...
-
Koskenvesa, Pert ...
-
Stenke, Leif
-
visa fler...
-
Mustjoki, Satu
-
Dimitrijevic, An ...
-
Stentoft, Jesper
-
Majeed, Waleed
-
Roy, Lydia
-
Wolf, Dominik
-
Dreimane, Arta
-
Gjertsen, Bjørn ...
-
Gedde-Dahl, Tobi ...
-
Ahlstrand, Erik, ...
-
Markevärn, Berit
-
Hjorth-Hansen, H ...
-
Janssen, Jeroen
-
Olsson-Strömberg ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Leukemia
- Av lärosätet
-
Uppsala universitet
-
Örebro universitet
-
Karolinska Institutet
-
Linköpings universitet